GlassScriptPhysician profile
Syreeta Van Ross
NPI 1063539823
$2,635.36
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $897 · 2023: $1,702 · 2024: $36.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.97 | 2022-2023 | |
| Pfizer INC. | $248.82 | 2022-2024 | |
| Novo Nordisk INC | $245.76 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $216.70 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $183.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $176.98 | 2022-2023 | Farxiga, Breztri |
| Amgen INC. | $101.56 | 2022-2023 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $91.35 | 2022-2023 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.67 | 2022-2023 | Synjardy, Tradjenta |
| Corium, LLC | $73.92 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $65.70 | 2022-2023 | Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $61.82 | 2023 | |
| Idorsia Pharmaceuticals US INC | $55.19 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $38.52 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.65 | 2023 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.13 | 2023 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $33.01 | 2022 | |
| Ironwood Pharmaceuticals, INC | $32.25 | 2023 | Linzess |
| Antares Pharma, INC. | $31.85 | 2023 | Tlando, Xyosted, Nocdurna |
| Alnylam Pharmaceuticals INC. | $30.80 | 2023 | Amvuttra |
| Teva Pharmaceuticals USA, INC. | $26.75 | 2022-2023 | Austedo |
| Scilex Pharmaceuticals INC. | $21.59 | 2023 | Ztlido |
| Ibsa Pharma INC. | $21.42 | 2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $20.92 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.88 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.48 | 2023 | Rexulti |
| Lundbeck LLC | $17.02 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $16.13 | 2023 | Livalo, Seglentis |
| Shield Therapeutics INC | $15.96 | 2023 | Accrufer |
| Astellas Pharma US INC | $15.22 | 2022 | |
| Halozyme INC | $15.20 | 2023 | |
| Esperion Therapeutics, INC. | $15.00 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.89 | 2022 | |
| Scynexis, INC. | $14.18 | 2022 | |
| Neos Therapeutics, LP | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syreeta Van Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.